MedPath

Effects of genetic polymorphism of CYP3A5 and UGT1A9 in brain-death donor and liver transplant recipients on pharmacokinetic profiles of tacrolimus and mycophenolate at steady state post-transplantatio

Phase 2
Recruiting
Conditions
Thai liver transplant patients (cadaveric liver transplant)
Thai liver transplant patients (cadaveric liver transplant)&#44
CYP3A5 and UGT1A9 polymorphisms&#44
Pharmacokinetics
Registration Number
TCTR20190707002
Lead Sponsor
Rachadapisek Sompote Fund.
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Recruiting
Sex
All
Target Recruitment
20
Inclusion Criteria

Thai liver transplant patients (cadaveric liver transplant)
Aged 18 years or older

Exclusion Criteria

Thai liver transplant patients (Living liver transplant)

Study & Design

Study Type
Observational
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath